venous thromboembolic disease
Conditions
Interventions
Warfarin group:Warfarin
Sponsors
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University, Guangzhou,Guangdong, China
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with non-high-risk pulmonary thromboembolism with/without deep vein thrombosis; 2.Patients volunteered for this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with active bleeding or the high risk for bleeding complications; 2. Patients who were considered to be high-risk pulmonary thromboembolism; 3. With both aspartate aminotransferase (AST) and glutamic-pyruvic transaminase (ALT) more than three times of the upper limit of normal in liver function test and Ccr less than 30ml/min in kidney function test; 4. Those with systemic blood pressure lower than 90/50 mmHg, or those uncontrolled dangerous hypertension(BP higher than 170/110 mmHg); 5. Patients who have to take azole antifungals, HIV protease inhibitors or strong CYP3A4 inducers during the period of treatment; 6. Pregnant, lactational women or may be pregnant during the period of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Computed Tomography Pulmonary Angiography;Bleeding events;Thromboembolic events;Warfarin VKORC1 and CYP2C9 gen; | — |
Secondary
| Measure | Time frame |
|---|---|
| liver and kidney functions;echocardiography;Lower extremity venous ultrasound;Ventilation/perfusion scan; | — |
Countries
China
Contacts
Public ContactChunli Liu
Outcome results
None listed